Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. Show more
Location: 540 Gaither Road, Rockville, MD, 20850, United States | Website: https://www.avalotx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
138.8M
52 Wk Range
$3.39 - $16.00
Previous Close
$10.56
Open
$10.67
Volume
74,625
Day Range
$10.06 - $10.70
Enterprise Value
25.52M
Cash
113.3M
Avg Qtr Burn
-11.85M
Insider Ownership
5.26%
Institutional Own.
64.11%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AVTX-803 (CERC-803) Details Leukocyte Adhesion Deficiency Type II | Phase 3 Data readout | |
AVTX-009 Details Hidradenitis suppurativa, Autoimmune disease | Phase 2 Data readout | |
Phase 2 Update | ||
Phase 2 Update | ||
Quisovalimab/ AVTX-002 (CERC-002) Details Crohns disease | Phase 1b Update | |
AVTX-007 (CERC-007) Details Multiple myeloma, Adult Onset Still's Disease | Phase 1b Update | |
AVTX-801 (CERC-801) Details Metabolic disorder, Rare genetic disease | Failed Discontinued | |
AVTX-802 (CERC-802) Details Metabolic disorder, Rare genetic disease | Failed Discontinued | |
AVTX-006 (CERC-006) Details Lymphatic malformations | Failed Discontinued |